Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Theravance Biopharma, Inc. (TBPH)  
$9.12 0.02 (0.22%) as of 4:30 Fri 4/26


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 63,980,000
Market Cap: 583.50(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $8.22 - $11.59
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  245
Guru Rank Value     : 4.8
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicine medicines. Co.'s program include: YUPELRI™ (revefenacin) inhalation solution, nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease; and Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (Nezulcitinib), a lung-selective, nebulized JAK inhibitor, in clinical development for the potential treatment of hospitalized patients with acute lung injury caused by Coronavirus Disease 2019.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 1,254 5,114 22,963 172,089
Total Sell Value $10,922 $50,468 $231,475 $1,835,193
Total People Sold 1 2 2 4
Total Sell Transactions 1 3 11 21
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 529
  Page 3 of 22  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Graham Richard A SVP, RESEARCH & DEVELOPMENT   •       –      –    2023-04-14 4 AS $11.88 $27,597 D/D (2,323) 369,494 -20%     
   Graham Richard A SVP, RESEARCH & DEVELOPMENT   •       –      –    2023-03-14 4 AS $10.32 $23,973 D/D (2,323) 371,817 -9%     
   Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS   •       –      –    2023-03-09 4 S $10.20 $40,800 D/D (4,000) 360,190 6%     
   Graham Richard A SVP, RESEARCH & DEVELOPMENT   •       –      –    2023-03-06 4 AS $10.05 $23,346 D/D (2,323) 374,140 -4%     
   Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS   •       –      –    2023-03-01 4 A $0.00 $0 D/D 75,000 364,190     -
   Winningham Rick E CHIEF EXECUTIVE OFFICER   •       •      –    2023-03-01 4 A $0.00 $0 D/D 330,000 1,643,377     -
   Sawaf Aziz SVP & CHIEF FINANCIAL OFFICER   •       –      –    2023-03-01 4 A $0.00 $0 D/D 80,000 277,717     -
   Graham Richard A SVP, RESEARCH & DEVELOPMENT   •       –      –    2023-03-01 4 A $0.00 $0 D/D 75,000 376,463     -
   Grimaud Brett A. SVP, GEN COUNSEL AND SECRETARY   •       –      –    2023-03-01 4 A $0.00 $0 D/D 75,000 304,958     -
   Gray Susannah   –       •      –    2023-02-26 4 A $0.00 $0 D/D 11,819 11,819     -
   Graham Richard A SVP, RESEARCH & DEVELOPMENT   •       –      –    2023-02-20 4 D $10.44 $125,875 D/D (12,057) 301,463     -
   Grimaud Brett A. SVP, GEN COUNSEL AND SECRETARY   •       –      –    2023-02-20 4 D $10.44 $106,467 D/D (10,198) 229,958     -
   Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS   •       –      –    2023-02-20 4 D $10.44 $74,322 D/D (7,119) 289,190     -
   Winningham Rick E CHIEF EXECUTIVE OFFICER   •       •      –    2023-02-20 4 D $10.44 $390,665 D/D (37,420) 1,313,377     -
   Sawaf Aziz SVP & CHIEF FINANCIAL OFFICER   •       –      –    2023-02-20 4 D $10.44 $70,815 D/D (6,783) 197,717     -
   Grimaud Brett A. SVP, Gen Counsel and Secretary   •       –      –    2023-02-14 3 IO $0.00 $0 D/D 0 240,156 -0%     
   Sawaf Aziz SVP & Chief Financial Officer   •       –      –    2023-01-01 3 IO $0.00 $0 D/D 0 204,500 3%     
   Winningham Rick E CHIEF EXECUTIVE OFFICER   •       •      –    2022-12-14 4 S $11.19 $559,500 D/D (50,000) 1,350,797 1%     
   Winningham Rick E CHIEF EXECUTIVE OFFICER   •       •      –    2022-12-13 4 GD $0.00 $0 D/D 9,000 1,400,797     -
   Graham Richard A SVP, RESEARCH & DEVELOPMENT   •       –      –    2022-12-01 4 S $10.73 $22,361 D/D (2,084) 313,520 -10%     
   Oconnor Donal   –       •      –    2022-11-22 4 D $10.50 $105,000 D/D (10,000) 43,886     -
   Hindman Andrew A. SVP, CHIEF FINANCIAL OFFICER   •       –      –    2022-11-20 4 D $10.85 $271,868 D/D (25,057) 384,714     -
   Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS   •       –      –    2022-11-20 4 D $10.85 $252,458 D/D (23,268) 296,309     -
   Winningham Rick E CHIEF EXECUTIVE OFFICER   •       •      –    2022-11-20 4 D $10.85 $171,473 D/D (15,804) 1,409,797     -
   Graham Richard A SVP, RESEARCH & DEVELOPMENT   •       –      –    2022-11-20 4 D $10.85 $296,748 D/D (27,350) 315,604     -
  529 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 3 of 22
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us